xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid
Company profile
Ticker
XBIO
Exchange
Website
CEO
Jeffrey F. Eisenberg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GENERAL AIRCRAFT INC., General Sales & Leasing, Inc.
SEC CIK
Corporate docs
Subsidiaries
Xenetic Biosciences (UK), Ltd. • Lipoxen Technologies, Ltd. • Xenetic Bioscience, Inc. • SymbioTec, GmbH • Hesperix S.A. ...
XBIO stock data
Latest filings (excl ownership)
8-K
Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results
10 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
10-K/A
2023 FY
Annual report (amended)
26 Apr 24
8-K
Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results
22 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Regulation FD Disclosure
12 Feb 24
8-K
Submission of Matters to a Vote of Security Holders
8 Dec 23
ARS
2022 FY
Annual report to shareholders
13 Nov 23
DEF 14A
Definitive proxy
13 Nov 23
8-K
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results
13 Nov 23
Latest ownership filings
SC 13D/A
CLS Therapeutics, LLC
18 Mar 24
4
Moshe Mizrahy
18 Dec 23
3
Moshe Mizrahy
18 Dec 23
4
Curtis Lockshin
13 Dec 23
4
JEFFREY F EISENBERG
13 Dec 23
4
JAMES F PARSLOW
13 Dec 23
4
Roger D. Kornberg
8 Dec 23
4
Grigory G. Borisenko
8 Dec 23
4
Firdaus J. Dastoor
8 Dec 23
4
James Eric Callaway
8 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.78 mm | 9.78 mm | 9.78 mm | 9.78 mm | 9.78 mm | 9.78 mm |
Cash burn (monthly) | 316.54 k | 339.34 k | 382.23 k | 401.95 k | 316.54 k | 339.34 k |
Cash used (since last report) | 2.33 mm | 2.50 mm | 2.82 mm | 2.96 mm | 2.33 mm | 2.50 mm |
Cash remaining | 7.44 mm | 7.28 mm | 6.96 mm | 6.82 mm | 7.44 mm | 7.28 mm |
Runway (months of cash) | 23.5 | 21.4 | 18.2 | 17.0 | 23.5 | 21.4 |
Institutional ownership, Q2 2023
12.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 9 |
Opened positions | 1 |
Closed positions | 12 |
Increased positions | 0 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 26.90 mm |
Total shares | 184.13 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CLS Therapeutics | 147.50 k | $471.00 k |
Renaissance Technologies | 25.78 k | $85.00 k |
RY Royal Bank Of Canada | 5.30 k | $17.00 mm |
JTC Employer Solutions Trusteee | 2.70 k | $9.00 k |
Steward Partners Investment Advisory | 1.90 k | $6.23 mm |
Tower Research Capital | 621.00 | $2.04 mm |
MS Morgan Stanley | 295.00 | $967.00 k |
NewSquare Capital | 26.00 | $85.00 k |
FMR | 7.00 | $22.00 k |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Dec 23 | Curtis Lockshin | Stock Options Common Stock | Grant | Acquire A | No | No | 3.88 | 10,000 | 38.80 k | 10,000 |
11 Dec 23 | James F Parslow | Stock Options Common Stock | Grant | Acquire A | No | No | 3.88 | 10,000 | 38.80 k | 10,000 |
11 Dec 23 | Jeffrey F Eisenberg | Stock Options Common Stock | Grant | Acquire A | No | No | 3.88 | 20,000 | 77.60 k | 20,000 |
6 Dec 23 | Firdaus J. Dastoor | Stock Options Common Stock | Grant | Acquire A | No | No | 4.29 | 2,500 | 10.73 k | 2,500 |
6 Dec 23 | James Eric Callaway | Stock Options Common Stock | Grant | Acquire A | No | No | 4.29 | 2,500 | 10.73 k | 2,500 |
News
Xenetic Biosciences Reports Q1 Loss, Misses Revenue Estimates
10 May 24
Xenetic Biosciences Q1 2024 GAAP EPS $(0.78) Beats $(0.79) Estimate, Sales $510.817K Miss $650.000K Estimate
10 May 24
CORRECTION: On Friday, Xenetic Biosciences Q4 GAAP EPS $(0.77) Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
25 Mar 24
Xenetic Biosciences Q4 EPS $0.77 Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
22 Mar 24